Header image

Concurrent Session 1D: Clinical Innovation: Ketamine, MDMA & Beyond

Tracks
.
Monday, November 9, 2026
1:30 PM - 3:00 PM
Rottnest

Speaker

Agenda Item Image
Dr Stephen Bright
Senior Lecturer
Edith Cowan University

Introduction & Welcome

1:30 PM - 1:35 PM

Dr Stephen Bright is a psychologist who has worked in the AOD field for over 20 years. He is currently Senior Lecturer at Edith Cowan University where he oversees the teaching of the Addiction Studies major. Dr Bright is also WA Assistant Commissioner for AOD. Stephen is a strong advocate of harm reduction and an evidence-based approach to AOD legislation. He has published research on the intersect between new and emerging drugs and drug policy, older adults and AOD, drug checking and psychedelic-assisted psychotherapies. Dr Bright established Australia’s first not-for-profit psychedelic research company, Psychedelic Research in Science & Medicine Ltd. He has since conducted clinical trials using MDMA and psilocybin to treat treatment refractory PTSD and depression, respectively. Given the recent changes to authorised prescribers’ scheme in Australia, Stephen now trains clinicians in the provision of psychedelic-assisted psychotherapies and consultancy to prospective authorised prescribers.
Agenda Item Image
Dr Stephen Bright
Senior Lecturer
Edith Cowan University

Through the Looking Glass: Translating Clinical Trial Experience with MDMA and Psilocybin-Assisted Psychotherapies to Real World Applications

1:35 PM - 1:45 PM

Abstract PDF

Ms Myfanwy Graham
NHMRC Postgraduate Scholar
Monash University

Psychedelics, ketamine or MDMA for mental health conditions access and outcomes: Australian longitudinal cohort study

1:45 PM - 1:55 PM

Abstract PDF

Myfanwy Graham is an NHMRC Postgraduate and Monash Research Excellence Scholar. She is a Fellow at the Schaeffer Center for Health Policy & Economics, University of Southern California and a Fulbright Scholar Alumna in public health policy. Myfanwy has served as a consultant for the TGA, WHO, UNODC and NASEM.
Agenda Item Image
Dr Jai Whelan
Postdoctoral Fellow
Ōtākou Whakaihu Waka | University Of Otago

A survey study of ketamine benefits, harms, and harm reduction in Aotearoa New Zealand

1:55 PM - 2:05 PM

Abstract PDF

Jai is a drug researcher, harm reduction advocate and drug user interested in a broad range of health research topics. He is particularly interested in research that pertains to harm reduction, drug policy, lived and living experience, and the intersection of these areas and Te Ao Māori
Mr Stassi Kypri
PhD Candidate / Research Assistant
The National Centre for Clinical Research on Emerging Drugs

Harms related to non-prescribed ketamine use in Australia: preliminary findings from a web-based survey

2:05 PM - 2:15 PM

Abstract PDF

Stassi Kypri is a PhD candidate and research assistant at the National Centre for Clinical Research on Emerging Drugs (NCCRED), UNSW, Sydney. His doctoral research involves a mixed-method exploration of ketamine and ketamine analogue use in Australia.
Dr Llewellyn Mills
Senior Research Associate
D&A Services, South Eastern Sydney LHD

Cannabidiol for the treatment of Cannabis Use Disorder: Findings from a Phase-III, multicentre, randomised, double-blind, placebo-controlled clinical trial.

2:15 PM - 2:25 PM

Abstract PDF

Dr Llew Mills is a postdoctoral researcher with the Discipline of Addiction Medicine, University of Sydney and South-Eastern Sydney Local Health District. His interests are cannabis dependence in a clinical and medicinal context, and in using routinely-collected clinical drug and alcohol data to improve drug and alcohol treatment.
Agenda Item Image
Prof Rebecca McKetin
Professor
NDARC

Mirtazapine for methamphetamine use disorder: A randomised double-blind placebo-controlled trial

2:25 PM - 2:35 PM

Abstract PDF

Professor Rebecca McKetin (BSc(Psychol)Hons. PhD) leads a program of research on stimulant use epidemiology and interventions at NDARC, UNSW. Her work involves trialling pharmacotherapies, developing and evaluating the online interventions, and evaluating community-based treatment options. She recently led the Tina Trial, a clinical trial of mirtazapine for methamphetamine use.
Mr Stassi Kypri
PhD Candidate / Research Assistant
The National Centre for Clinical Research on Emerging Drugs

Non-prescribed ketamine use intended to improve mental health: preliminary results from an Australian survey

2:35 PM - 2:40 PM

Abstract PDF

Stassi Kypri is a PhD candidate and research assistant at the National Centre for Clinical Research on Emerging Drugs (NCCRED), UNSW, Sydney. His doctoral research involves a mixed-method exploration of ketamine and ketamine analogue use in Australia.
Ellie Ahounbar
PhD Candidate
University Of Melbourne & Orygen

A Randomised Controlled Trial of a Novel Early Integrated Psychotherapy to Reduce Substance Use in Youth with Co-Occurring Mental Illness Seeking Primary Mental Healthcare: The INTEGRATE Study

2:40 PM - 2:45 PM

Abstract PDF

I am a final year PhD Candidate working on early interventions for substance use in young people with mental ill-health. My background is Persian and I have worked as a clinical psychologist and researcher in the field of substance use for approximately 7 years before moving to Australia.
APSAD 2026

Session Q&A

2:45 PM - 3:00 PM


Chair

Agenda Item Image
Stephen Bright
Senior Lecturer
Edith Cowan University

loading